Polpharma secures research grants to develop inhaled complex generics for COPD and asthma and an injectable polypeptide generic for type 2 diabetes.
Among the awarded projects by Polpharma are:
- Development and advancement of inhaled complex generic drugs for the treatment of respiratory diseases such as COPD and asthma – this project aims to create modern medications that will improve the quality of life for patients with respiratory diseases.
- Development and advancement of an injectable generic drug based on an active substance from the polypeptide group for the treatment of type 2 diabetes – this project focuses on developing modern therapies for patients with type 2 diabetes.
These prestigious grants are evidence of Polpharma’s commitment to the development of innovative pharmaceutical solutions aimed at improving patients’ quality of life.
Krzysztof Metza
Group Press Office
Media Contact